IDXX trades against a final fair-value range of $231.99-$439.23, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $232, high $439, with mid-point at $335.
Currently screens above fair value, so patience matters more than entry speed.
Fair value
$335
Margin of safety
-59.3%
Confidence
79/100
Moat
9/10
Educational analysis only — not financial advice. Always do your own due diligence.
$533.92Price
Low $231.99
Mid $335.08
High $439.23
IDXX trades against a final fair-value range of $231.99-$439.23, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
Razor-and-blade diagnostic instrument model
Razor-and-blade diagnostic instrument model
High switching costs locking in
High switching costs locking in veterinary clinics
Cycle upside
Accelerating global pet humanization, increased diagnostic utilization per clinical visit, and ongoing margin expansion from software integration.
§2 Scenario ribassista
A prolonged macroeconomic downturn could reduce discretionary veterinary clinic traffic, stalling instrument placements and consumable volume growth, while a high starting valuation multiple compresses.
Come questa tesi può fallire
Severe Valuation Compression
· High
Market recalibrates the extreme 39x trailing P/E multiple down to the model's 25x terminal multiple constraint.
FV impact
-37% to base case midpoint of $335.08
Macroeconomic Traffic Downturn
· Medium
A prolonged recession reduces discretionary veterinary clinic traffic, stalling instrument placements and recurring consumable volumes.
FV impact
Drives valuation toward the $231.99 bear case low
Margin Degradation
· Low
Competition forces aggressive pricing, causing operating margins to fall below the historically stable 30-31.6% range.
FV impact
Erodes 41.7% ROIC and compresses intrinsic fair value further
Segnali di allerta precoce da monitorare
Metrica
Attuale
Soglia di attivazione
Operating margins falling below 30% indicating pricing power erosion.
Based on our latest analysis, IDXX looks meaningfully overvalued. The current price is $534 versus a composite fair-value midpoint of $335 (range $232–$439), which implies roughly 37.2% downside to the midpoint.
Our composite fair-value range for IDXX is $232–$439, with a midpoint of $335. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for IDXX's archetype.
Our current rating for IDXX is Sell with a confidence score of 79/100. IDXX is rated Sell at $533.92 versus the reconciled fair value midpoint of $335.08, implying -37.24% upside/downside. Confidence is separately disclosed at 79/100. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for IDXX are: Severe Valuation Compression; Macroeconomic Traffic Downturn; Margin Degradation. The single biggest risk is Severe Valuation Compression: Market recalibrates the extreme 39x trailing P/E multiple down to the model's 25x terminal multiple constraint.
Our current rating for IDXX is Sell, issued with a confidence score of 79/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($232–$439) versus the current price of $534.
IDXX is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for IDXX.
